The Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines are a collection of consensus statements developed by experts in the treatment of specific types of cancer. Each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients.
These systematically developed recommendations promote enhanced clinical decisions concerning patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. Prior to publication of each Guideline, a Call for Comment phase is opened available only for SITC members to review a draft copy of the Guideline and provide feedback in the goal of further improving the draft. Click here to learn more about the Call for Comment process.
In response to the ever-growing demand for expert advice on the optimal use of immunotherapy treatments, our Cancer Immunotherapy Guidelines Task Forces have developed consensus statements for genitourinary malignancies (renal and prostate carcinoma) and hematologic malignancies (multiple myeloma, lymphoma and acute leukemia).
An update of the melanoma consensus statement and new guidelines for bladder cancer and lung cancer are also underway. These disease-specific Cancer Immunotherapy Guidelines offer a vital resource for the practicing oncology community.
Members receive free access to download SITC's Cancer Immunotherapy Guidelines – Immunotherapy for Renal Cell Carcinoma Digital Pocket Guide on any desktop or mobile device through a members only link*
To receive this benefit, please sign in to your SITC member account for the link to appear on this page.
*Available only through the Guideline Central App.
Published Aug. 27, 2013 in Nature Reviews Clinical Oncology as "The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma."
An update to the Melanoma Guidelines is expected to be published in 2017.
Published Nov. 15, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma."
Published Dec. 20, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma."
Published Aug. 15, 2017 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma."
Published Dec. 20, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia."
SITC follows the 2011 Institute of Medicine’s “Standards for Developing Trustworthy Clinical Practice Guidelines” to assure a fair, transparent and balanced process for creating the consensus statement; therefore, each Cancer Immunotherapy Guidelines Task Force comprises a comprehensive mix of academic physicians and researchers,nurses, patients, and patient advocates invited from a diversity of institutions across the United States.
Each expert Task Force addresses knowledge gaps in our understanding of immunotherapy treatments for their disease specialty, and then develops evidence-based recommendations by recording consensus opinions of the Task Force and documenting alternative opinions when they occur.
From Bedside to Bench and Back Again | Boston on September 26-27, 2017 ------------------------------ Joseph Murphy PhD Director Charles River Laboratories Quincy MA ----------------------------
Regarding lymphatic endothelial cell-related cancer and post-transplant recipients. Kaposi's sarcoma-associated herpes virus (KSHV or HHV-8) evades immune killing of tumor cells by relying on its immunomodulatory viral antigens. Organ donors in high seroprevalence ...
There is likely an unpublished cohort of patients throughout the world who were treated with ipilimumab prior to the introduction of nivolumab/ipilimumab combination and achieved an either complete remission or partial remission. These patients then ...
The case report presented here on advanced melanoma, in an elderly patient on page 810, indicates that despite of lack of prior ipilimumab treatment it cannot be excluded that subsequent observed astonishing treatment with nivolumab can partially be due ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com